In osteosarcoma studies, it has been found that some biomarkers related to the NF-κB signaling pathway, such as the nuclear expression level of the NF-κB subunit and the expression level of target genes such as Cyclin D1 and VEGF, are closely related to patient prognosis and response to therapy. This evidence concerns the gene NFKB1 and osteosarcoma.